Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia: Open Label Extension (PRISMA-3_OLE)

NCT03870880 is registered in ClinicalTrials.gov with Rovi Pharmaceuticals Laboratories as lead sponsor.

NCT NCT03870880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03870880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia: Open Label Extension (PRISMA-3_OLE)
Lead sponsor
Rovi Pharmaceuticals Laboratories
Phase
Phase 3
Overall status
Completed
Start date
August 25, 2017
Completion date
January 8, 2020
Enrollment
215 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia